Identification and characterization of α1-antitrypsin in fibrin clots

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 7, 2013, Pages 1319-1328

  Talens, S ^a   Malfliet, J J M C ^a   van Hal, P Th W ^a   Leebeek, F W G ^a   Rijken, D C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alpha 1 antitrypsin; Fibrin; Fibrinogen; Hemostasis; Inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN ELASTASE; ELASTASE; FIBRIN; FIBRINOGEN; THIOUREA; UNCLASSIFIED DRUG; UREA;

ARTICLE; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN CLOT; HUMAN; HUMAN TISSUE; LYSIS; NORMAL HUMAN; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; WESTERN BLOTTING;

ALPHA 1-ANTITRYPSIN; FIBRIN; FIBRINOGEN; HEMOSTASIS; INFLAMMATION;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BLOOD COAGULATION; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, AGAROSE; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMANS; PANCREATIC ELASTASE; PROTEIN BINDING; PROTEIN DENATURATION;

EID: 84880428211     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12288     Document Type: Article

References (36)

1. de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12: 377-83.
2. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4-13.
3. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-99.
4. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-6.
5. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR. Structure and variation of human alpha 1-antitrypsin. Nature 1982; 298: 329-34.
6. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med 2011; 105: 1129-39.
7. Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 2011; 9 (Suppl. 1): 26-34.
8. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem 2009; 78: 147-76.
9. Rijken DC, Dirkx SP, Luider TM, Leebeek FW. Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot. Biochem Biophys Res Commun 2006; 350: 191-4.
10. Talens S, Hoekstra J, Dirkx SP, Darwish Murad S, Trebicka J, Elias E, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW, Rijken DC. Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. J Hepatol 2011; 54: 908-14.
11. Talens S, Leebeek FW, Demmers JA, Rijken DC. Identification of fibrin clot-bound plasma proteins. PLoS ONE 2012; 7: e41966.
12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
13. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990; 265: 109-13.
14. Rijken DC, Groeneveld E, Kluft C, Nieuwenhuis HK. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin. Biochem J 1988; 255: 609-15.
15. Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol 2007; 14: 236-41.
16. Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, Shore A, Hess K, Ajjan R, Pease RJ, Keen JN, Standeven KF, Carter AM. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9: 216-25.
17. Dafforn TR, Pike RN, Bottomley SP. Physical characterization of serpin conformations. Methods 2004; 32: 150-8.
18. Smolarczyk K, Boncela J, Szymanski J, Gils A, Cierniewski CS. Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis. Arterioscler Thromb Vasc Biol 2005; 25: 2679-84.
19. Tsurupa G, Yakovlev S, McKee P, Medved L. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites. Biochemistry 2010; 49: 7643-51.
20. Scott LJ, Russell GI, Nixon NB, Dawes PT, Mattey DL. Oxidation of alpha1-proteinase inhibitor by the myeloperoxidase-hydrogen peroxidase system promotes binding to immunoglobulin A. Biochem Biophys Res Commun 1999; 255: 562-7.
21. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80: 1366-74.
22. Ricagno S, Caccia S, Sorrentino G, Antonini G, Bolognesi M. Human neuroserpin: structure and time-dependent inhibition. J Mol Biol 2009; 388: 109-21.
23. Carlstrom AS, Lieden K, Bjork I. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res 1977; 11: 785-97.
24. Peterson CB, Blackburn MN. Antithrombin conformation and the catalytic role of heparin. I. Does cleavage by thrombin induce structural changes in the heparin-binding region of antithrombin?. J Biol Chem 1987; 262: 7552-8.
25. Lord ST, Allen SL, Gorkun OV. The interiors of the fibers in a fibrin clot are accessible to large proteins like activated factor XIII. J Thromb Haemost 2011; 9 (Suppl.2): 121.
26. Matheson NR, Travis J. Inactivation of human thrombin in the presence of human alpha1-proteinase inhibitor. Biochem J 1976; 159: 495-502.
27. Ellis V, Scully M, MacGregor I, Kakkar V. Inhibition of human factor Xa by various plasma protease inhibitors. Biochim Biophys Acta 1982; 701: 24-31.
28. Heck LW, Kaplan AP. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin. J Exp Med 1974; 140: 1615-30.
29. Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem 1988; 263: 11613-6.
30. Rijken DC, Juhan-Vague I, Collen D. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. J Lab Clin Med 1983; 101: 285-94.
31. Clemmensen I, Christensen F. Inhibition of urokinase by complex formation with human alpha1-antitrypsin. Biochim Biophys Acta 1976; 429: 591-9.
32. Plow EF. Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway. J Clin Invest 1982; 69: 564-72.
33. Brower MS, Harpel PC. Alpha-1-antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin complexes. Blood 1983; 61: 842-9.
34. Kluft C. The fibrinolytic system and thrombotic tendency. Pathophysiol Haemost Thromb 2003; 33: 425-9.
35. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887-96.
36. Ikari Y, Fujikawa K, Yee KO, Schwartz SM. Alpha(1)-proteinase inhibitor, alpha(1)-antichymotrypsin, or alpha(2)-macroglobulin is required for vascular smooth muscle cell spreading in three-dimensional fibrin gel. J Biol Chem 2000; 275: 12799-805.